Vitamin D sebagai Terapi Adjuvan Kandidiasis Vulvovaginalis untuk Mengurangi Risiko Rekuren. Laporan Kasus Berbasis Bukti

Authors

  • Peggy Liberty Program Studi Pendidikan Kedokteran, Fakultas Kedokteran Universitas Sumatera Utara, Medan, Indonesia
  • Imam Budi Putra Departemen Dermatologi dan Venerreologi, Fakultas Kedokteran Universitas Sumatera Utara, Medan, Indonesia
  • Nelva Karmila Jusuf Departemen Dermatologi dan Venerreologi, Fakultas Kedokteran Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.55175/cdk.v49i7.261

Keywords:

Kandidiasis vulvovaginalis, vitamin D

Abstract

Latar belakang: Kandidiasis vulvovaginalis (KVV) merupakan infeksi yang disebabkan oleh Candida sp. terutama Candida albicans, dengan gejala pruritus, dispareunia, disuria, dan sekret vagina abnormal. Diperkirakan 75% wanita pernah mengalami 1 episode KVV dan 40-45% mengalami 2 atau lebih episode. Tingginya kejadian KVV menjadi masalah. Angka resistensi antijamur yang tinggi juga meningkatkan risiko kejadian KVV rekuren. Untuk mengatasi masalah ini, diperlukan terapi adjuvan KVV yang terbukti dapat menurunkan risiko kejadian KVV rekuren. Penggunaan vitamin D sebagai terapi adjuvan pada KVV dinilai berpotensi menurunkan risiko kejadian KVV rekuren karena sifat liposolubilitasnya yang mampu mengganggu integritas membran sel Candida albicans. Metode: Penelusuran literatur dilakukan pada 9 database berdasarkan pertanyaan klinis dengan kata kunci yang sesuai. Artikel dipilih berdasarkan kriteria inklusi dan eksklusi, kemudian dilakukan telaah kritis pada artikel terpilih untuk dinilai validitas, kepentingan, dan penerapannya. Hasil: Didapatkan 1 artikel yang memenuhi kriteria inklusi dan komponen telaah kritis. Simpulan: Vitamin D sebagai terapi adjuvan pada pengobatan KVV terbukti bermanfaat menurunkan risiko kejadian KVV rekuren.

Background: Vulvovaginal candidiasis is an infection caused by Candida sp. especially Candida albicans, with symptoms include pruritus, dyspareunia, dysuria, and abnormal vaginal discharge. It is estimated that 75% women experience one episode of vulvovaginal candidiasis and 40-45% experience two or more episodes. The high prevalence of vulvovaginal candidiasis has become a problem. Antifungal resistance also increases risk to recurrent vulvovaginal candidiasis. Proven adjuvant therapy to lower risk of recurrent vulvovaginal candidiasis is needed. Vitamin D is potentially used as adjuvant therapy, indicated by its liposolubility which disrupt the integrity of Candida albicans’ cell membrane. Methods: Search of literature was conducted on 9 databases according to clinical question and appropriate keywords. Articles were selected according to inclusion and exclusion criteria, the selected articles were critically appraised for its validity, importance, and applicability. Results: One article fulfills the inclusion criteria and components of critical appraisal. Conclusion: Vitamin D as adjuvant in treatmentof vulvovaginal candidiasis is proven to lower recurrent vulvovaginal candidiasis risk.

Downloads

Download data is not yet available.

References

Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep [Internet]. 2015 [cited 2021 June 24]. Available from: https://www.cdc.gov/std/tg2015/candidiasis.htm

Farrar J, Hotez P, Junghanss T, Kang G, Lalloo D, White N. Manson’s tropical disease. 23rd ed. USA: Elsevier; 2013 .pp. 445.

Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia. Panduan praktik klinis bagi dokter spesialis kulit dan kelamin di Indonesia. PERDOSKI [Internet]. 2017 [cited 2021 June 24].Available from: https://perdoski.id/uploads/original/2017/10/PPKPERDOSKI2017.pdf

Monroy-Pérez E, Paniagua-Contreras GL, Rodriguez-Purata P, Vaca-Paniagua F, Vazquez-Villasenor M, Diaz-Velasquez C, et al. High virulence and antifungal resistance in clinical strains of 33 Candida albicans. Can J Infect Dis Med Microbiol. 2016;2016:4-5.

Willems HM, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal candidiasis: A current understanding and burning questions. J Fungus. 2020;6:27.

Felix TC, Röder DD, Pedroso RS. Alternative and complementary therapies for vulvovaginal candidiasis. Folia Microbiol. 2018;64(Suppl1):7.

Muhvić-Urek M, Saltović E, Braut A, Pavičić DK. Association between vitamin D and Candida-associated denture stomatitis. Dent J (Basel). 2020;8(4):121.

Bouzid D, Merzouki S, Bachiri M, Ailane SE, Zeroug MM. Vitamin D3 a new drug against Candida albicans. J Mycol Med. 2017;27(1):79-82.

Amegah AK, Baffour FK, Appiah A, Adu-Frimpong E, Wagner CL. Sunlight exposure, consumption of vitamin D-rich foods and vulvovaginal candidiasis in an African population: A prevalence case–control study. Eur J Clin Nutr. 2019;74(3):518-26.

Pandhita G, translator. Critical appraisal worksheets logbook. EBM Toolbox [Internet]. 2017 [cited 2021 June 25]. Available from: https://ebm-tools.knowledgetranslation.net/worksheet,https://vdocuments.site/telaah-kritis-artikel-harm-mahasiswa.html

Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2012;128(1):305–10.

Bernardis FD, Graziani S, Tirelli F, Antonopoulou S. Candida vaginitis: Virulence, host response and vaccine prospects. Med Mycol J. 2018;56(1):26-31.

Downloads

Published

01-07-2022

How to Cite

Liberty, P., Putra, I. B., & Jusuf, N. K. (2022). Vitamin D sebagai Terapi Adjuvan Kandidiasis Vulvovaginalis untuk Mengurangi Risiko Rekuren. Laporan Kasus Berbasis Bukti. Cermin Dunia Kedokteran, 49(7), 404–406. https://doi.org/10.55175/cdk.v49i7.261